Hines J D, Oken M M, Mazza J J, Keller A M, Streeter R R, Glick J H
J Clin Oncol. 1984 Jun;2(6):545-9. doi: 10.1200/JCO.1984.2.6.545.
High-dose cytosine arabinoside ( HDARAC ) and 4'-(9 acridinylamino) methane sulfon -m-anisidine (m-AMSA) was administered as induction therapy to 40 patients with relapsed or refractory acute nonlymphocytic leukemia (ANLL) with the following results: 28 patients (70%) achieved complete remission, one patient achieved a partial remission; five patients died with hypoplastic bone marrows containing less than 5% blasts; four patients died with hypoplastic marrowing containing greater than 5% blasts; and three patients failed to achieve marrow aplasia and died without significant cytoreduction in percentage of blasts. Consolidation therapy was not used and maintenance therapy was given to less than 10% (three patients) of remission patients. The median duration of remission for all patients was 6.0 months and the median time for the complete remission patients exceeded eight months. This regimen has acceptable toxicity and the results are equivalent to those obtained from conventional induction therapy of de novo ANLL patients.
高剂量阿糖胞苷（HDARAC）和4'-（9-吖啶基氨基）甲磺基间茴香胺（m-AMSA）被用作40例复发或难治性急性非淋巴细胞白血病（ANLL）患者的诱导治疗，结果如下：28例患者（70%）达到完全缓解，1例患者达到部分缓解；5例患者死于骨髓增生低下，骨髓中原始细胞少于5%；4例患者死于骨髓增生低下，骨髓中原始细胞大于5%；3例患者未达到骨髓抑制，未出现原始细胞百分比显著降低而死亡。未采用巩固治疗，缓解患者中不到10%（3例患者）接受了维持治疗。所有患者的缓解持续时间中位数为6.0个月，完全缓解患者的中位时间超过8个月。该方案毒性可接受，结果与初发ANLL患者传统诱导治疗的结果相当。
